In this fascinating episode recorded at #BSR24, Dr Melanie Sloan joins Prof Ernest Choy to discuss the latest results from the INSPIRE study, which seeks to understand neuropsychiatric symptom prevalence and impact in people with systemic autoimmune rheumatic diseases (SARDs).

Dr Melanie Sloan is a researcher in the Department of Public Health and Primary Care at the University of Cambridge. Her research focuses on improving patient-clinician relationships, as well as trialling interventions for patients with SARDs.

Want to find out more about Melanie’s research? Here’s your further reading list:

1. Prevalence and identification of neuropsychiatric symptoms in SARDs
2. Neuropsychiatric symptoms in lupus
3. Attribution of neuropsychiatric symptoms and prioritisation of evidence in lupus
4. Prodromal neuropsychiatric symptoms in lupus

Keywords: autoimmune diseases, lupus, rheumatology, nightmares, daymares, mental health, psychosis, communication.

Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Dr Jason E Liebowitz joins Dr Marwan Bukhari to discuss the metaverse and how the field of rheumatology can utilise virtual and augmented reality to improve the lives of patients.

Listen now to hear about the current technological developments and what this means for future clinical practice!

You can read this article [https://doi.org/10.1093/rheumatology/kead534] in Rheumatology.

Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.

Professor Doron Rimar joins Dr Cristiana Sieiro Santos to discuss their article, which retrospectively compares the outcomes of SSc patients who underwent AHSCT to patients who met the eligibility criteria for AHSCT but received upfront combination therapy with MMF and rituximab.

Listen now to hear the findings and what this means for future clinical practice!

You can read this article [https://doi.org/10.1093/rheumatology/kead457] in Rheumatology.

Thanks for listening to Talking Rheumatology Research! Join the conversation on Twitter using #TalkingRheumResearch, tweet us @RheumJnl, or find us on Instagram.

Want to read more rheumatology research? Explore Rheumatology and Rheumatology Advances in Practice.